IL6 and rheumatoid arthritis: Treatment with tocilizumab blocks interkeukin-6 (IL-6) signaling within inflammatory and immune cells, and improves the clinical symptoms of autoimmune diseases, such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA) and multicentric Castleman's disease (MCD) [14].